# Pharmaron Beijing Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmaron-beijing-co

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.pharmaron.com
- Total disclosed funding: $44M
- Latest round: Series C (Feb 24, 2011)
- Investors on record: 5

## About

Pharmaron Beijing Co., Ltd. is a prominent contract research and manufacturing organization specializing in comprehensive drug development services, including R&D, preclinical and clinical development for pharmaceuticals and biologics.Founded in 2004 in Beijing, China, Pharmaron specializes in contract research and manufacturing services. The company was founded by Boliang Lou, who has a history in the life sciences sector. Pharmaron has conducted a total of seven deals, with their most recent funding round being an IPO on January 14, 2019, during which they raised HKD 4621.5 million. This capital has facilitated the company's robust growth in the pharmaceutical industry.Pharmaron offers an extensive range of research, development, and manufacturing services across drug discovery, preclinical, clinical development, and commercialization phases for small molecules, biologics, and cell and gene therapies. Their core offerings include laboratory services, chemistry, manufacturing and controls (CMC), and clinical development solutions, assisting clients in the life sciences sector to efficiently navigate drug market complexities.For the year 2021, Pharmaron reported a revenue of HKD 1,153,792,260.90 and an EBITDA of HKD 354,356,763. The company's revenue primarily arises from B2B partnerships with pharmaceutical, biotech, and medical device companies, structured around project-based contracts and collaborations.Pharmaron plans to leverage the funds raised during its IPO to expand its service offerings and enter new markets. The company is focusing on enhancing capabilities in cell and gene therapies and aims to establish a significant presence in North America and Europe by 2025. The capital raised will be utilized to develop upcoming products and strengthen operational efficiencies, ensuring Pharmaron remains competitive in the evolving pharmaceutical landscape.

## Funding rounds

- Series C, Feb 24, 2011, $40M — DCM, Legend Capital, GL Capital Partners, HighLight Capital
- Series B, Jun 1, 2008, $3.6M — DCM, Legend Capital, Avenue Capital Group

## Investors

- DCM (https://capitalatlas.ai/funds/dcm) — Series B, Series C
- Legend Capital — Series B, Series C
- Avenue Capital Group (https://capitalatlas.ai/funds/avenue-capital-group) — Series B
- GL Capital Partners — Series C
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series C